Nitroglycerin + hydralazine in CHF patients is beneficial in african americans, but it’s effect in other racial and ethnic groups is less clear. In the retrospective cohort of CHF patients admitted with acute decompensated CHF (with cardiac index <2.2), researchers compared outcomes in those discharged on ACE/ARB, versus those discharged on ACE/ARB combined with isosorbide dinitrate + hydralazine (I/H group). Those in the I/H group had lower all cause mortality (34% versus 41%), and lower mortality/CHF readmissions (70% versus 85%). The benefit was found irrespective of race. I/H addition to ARB/ACE in CHF is associated with lower mortality (abstract).
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]